Then the phase 3 OCEANIC-AF, trial comparing the novel factor XI inhibitor asundexian (Bayer) vs the direct-acting oral anticoagulant apixaban in patients with atrial fibrillation was stopped ...

Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, ...

Important questions about the effectiveness of factor XI inhibitors have yet to be answered, and success isn’t ensured. Several large-scale or Phase 3 clinical trials are now under way to ...

The monoclonal antibody is the only ‘dual activity’ Factor XI inhibitor which targets both the inactive zymogen, Factor XI, and the active form, Factor XIa. By acting on both forms ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Factor XI. REGN7508 (catalytic domain) is ...

The high rates of haemorrhage make the treatment challenging, however, and Factor XI inhibitors have been proposed as a way to reduce clots without increasing the risk of bleeds. Merck is playing ...

Anthos Therapeutics says a phase 2b trial of its factor XI inhibitor anticoagulant abelacimab has been stopped early due to an “overwhelming” reduction in bleeding complications compared to ...

A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial, ...

Despite Regeneron’s stock having dropped over 35% from its peak, Pickering identifies significant potential in the company’s early-stage pipeline, particularly with their Factor XI inhibitors.

Targeting Factor XI may offer tailored therapies that prevent ... A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients ...